IZOZF - Izotropic Engages Clinical Research Organization in Preparation for Clinical Study
(TheNewswire)
VANCOUVER, BC – TheNewswire - JULY 19,2022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a MedTech company commercializing IzoView, an advancedbreast CT (computed tomography) imaging platform for the more accurate detection and diagnosis of breastcancer , announces it has engaged a world-leading clinical researchorganization (CRO ) ICON plc (“ICON”) to help prepare for its upcomingclinical study and submission for market authorization in theU.S.
With over 20 years ofexperience and having completed 500+ trials over the last five years,ICON’s Medical Device team has been engaged to support multipleaspects of Izotropic’s clinical research study includingcontracting, start-up, data collection and analysis, and reportwriting for FDA submission. ICON’s seniorexperts work directly with the FDA, including the Division ofRadiological Health.
“Engaging ICON means we are confidently movingforward with our business plans to bring IzoView to marketefficiently,” said Dr. John McGraw, CEO. “We plan to run amulti-site study with leading U.S. hospitals which will help toexpedite patient recruitment and broadens the clinical experience withIzoView. When operating a multi-site study, it is critical that thesame set of processes and procedures from start to finish are followedat each site for every patient to mitigate exclusion and maintain dataintegrity, and ICON’s expertise enhances that capability.”
About ICON plc
ICON is the world’s leading clinical researchorganization, powered by healthcare intelligence. From molecule tomedicine, ICON advances clinical research providing outsourceddevelopment and commercialization services to pharmaceutical,biotechnology, medical device, government, and public healthorganizations. ICON develop new innovations, drive emerging therapiesforward, and improve patient lives. With headquarters in Dublin,Ireland, ICON employ approximately 39,300 employees in 138 locationsin 53 countries.
ON BEHALF OF THE BOARD
Investor Relations Contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible,
to identify such information and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project,"
"target," "potential," "will,""would," "could," "should,""continue," "contemplate" and other similarexpressions and derivations thereof in connection with any discussionof future events, trends or prospects or future operating or financialperformance, although not all forward-looking statements contain theseidentifying words. These statements are not guarantees of performanceand involve risks including those related to capital requirements, anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.